ClinicalTrials.Veeva

Menu

Embolization Strategies for Pelvic Venous Disorders: Foam + Glue vs Foam + Coils (foam and coil)

K

Kafrelsheikh University

Status

Invitation-only

Conditions

Pelvic Congestive Syndrome

Treatments

Other: Combined Foam Sclerotherapy and Detachable Coil Embolization
Other: Foam + N-butyl Cyanoacrylate

Study type

Interventional

Funder types

Other

Identifiers

NCT07221695
glue vs coil for ovarian ttt

Details and patient eligibility

About

Foam Plus Glue Versus Foam Plus Coils for Ovarian Vein Embolization in the Treatment of Pelvic Venous Disorders: A Randomized Controlled Trial

Enrollment

60 estimated patients

Sex

Female

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • Female patients aged 18 to 50 years

  • Clinically suspected pelvic venous disorder (PVD), presenting with chronic pelvic pain ≥ 6 months

  • Pelvic pain intensity ≥ 4 on a 10-point Visual Analogue Scale (VAS) at baseline

  • No evidence of significant venous obstruction or internal iliac insufficiency

  • Willingness to participate, provide written informed consent, and comply with study visits and procedures exclusion criteria

  • Pregnancy or planning to conceive within the next 12 months

  • Significant Nutcracker syndrome diagnosed by duplex / CTV / MRV

  • Significant May-Thurner syndrome diagnosed by duplex / CTV / MRV

  • Non-ovarian sources of reflux requiring intervention, including internal iliac vein insufficiency; During venography all patients will undergo selective pelvic venography prior embolization to exclude patients who have combined gonadal and internal iliac vein reflux)

  • History of previous pelvic vein embolization or surgical ligation

  • Coagulopathy, defined as:

    • INR > 1.5
    • Platelet count < 50 × 10⁹/L
  • Severe comorbidities, including:

    • Active pelvic infection (e.g., pelvic inflammatory disease)
    • End-stage renal disease (eGFR < 30 mL/min/1.73 m²)
    • Decompensated heart failure (NYHA class III-IV)
    • Active malignancy requiring treatment

Known allergy or hypersensitivity to:

  • Iodinated contrast media
  • Polidocanol (Aethoxysklerol®)
  • N-butyl cyanoacrylate (e.g., Gluebran® 2)
  • Nickel, platinum, or stainless steel (components of embolization coils) . Presence of non-venous pelvic pathology requiring immediate management

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Embolization using polidocanol foam followed by N-butyl cyanoacrylate
Active Comparator group
Description:
. After selective catheterization of the ovarian vein and reflux confirmation, Sclerosant foam will be prepared using 3% polidocanol (Aethoxysklerol®, Kreussler Pharma), mixed with room air in a 1:4 ratio (1 mL polidocanol to 4 mL air) using the Tessari double-syringe technique, creating a dense and stable foam. The foam will be injected slowly into the reservoir of the refluxing segment of the ovarian vein under fluoroscopic guidance to induce endothelial irritation and reduce venous flow. A total of 5-10 mL of 3% polidocanol foam will be injected per vein, adjusted based on vein diameter and reflux length. Next, N-butyl cyanoacrylate (Gluebran®️ 2) will be mixed with Lipiodol in a 1:2 to 1:3 ratio, depending on vein size and flow rate. Approximately 1-2 mL of the glue mixture will be injected per vein using a coaxial microcatheter system from distal to proximal segments. Occlusion will be confirmed by post-embolization venography."
Treatment:
Other: Foam + N-butyl Cyanoacrylate
Combined Foam Sclerotherapy and Detachable Coil Embolization
Active Comparator group
Description:
Patients in this group will undergo embolization using sclerosant foam followed by detachable platinum coils. Vascular access and catheterization technique will mirror Group A. After injecting polidocanol foam (as above), subsequently, detachable platinum fibered coils - specifically Interlock™ (Boston Scientific) or Concerto™ (Medtronic) - will be deployed to achieve permanent mechanical occlusion. Coil selection (diameter and length) will be based on intra-procedural vein sizing. Final occlusion will be confirmed via completion venography.
Treatment:
Other: Combined Foam Sclerotherapy and Detachable Coil Embolization

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems